Literature DB >> 1386093

Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.

C C Delibrias1, E Fischer, G Bismuth, M D Kazatchkine.   

Abstract

We have investigated the expression, molecular association, ligand binding properties, and ability to transduce intracellular signals of CR1 and CR2 C3 receptors on cells of the human HPB-ALL T cell line. CR1 and CR2 on HPB-ALL cells bound polymeric C3b and C3dg and several anti-CR1 and anti-CR2 mAb recognizing different epitopes of the receptors on normal peripheral blood cells. Immunoprecipitated CR1 and CR2 exhibited similar m.w. to those of the receptors on normal peripheral blood T and B lymphocytes. CR1 and CR2 were partially associated in the form of CR1/CR2 complexes in the cell membrane as assessed by the ability of the receptors to cocap and cointernalize and to form a detergent-sensitive complex upon immunoprecipitation analysis. Triggering of CR2 with mAb OKB7 that recognizes an epitope associated with the ligand binding site of the receptor induced an increase in intracellular free calcium concentration in HPB-ALL cells. The signal provided by mAb OKB7 did not synergize with that triggered by anti-CD3 mAb UCHT1. Triggering of CR1 did not result in changes in intracellular free calcium concentration. Our observations have significance for the biology of normal human T cells because the majority of peripheral blood T cells that express CR1 also expressed CR2 and because a change in (Ca2+)i was induced by mAb OKB7 in purified normal T cells. These functions may be relevant for the regulatory role of C3 fragments on the immune response to T-dependent Ag and for the penetration into T cells of lymphocytotropic viruses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1386093

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  B-cell antigens within normal and activated human T cells.

Authors:  G P Sandilands; M Perry; M Wootton; J Hair; I A More
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

2.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Enhanced CD21 expression and shedding in chronic lymphatic leukemia: a possible pathomechanism in disease progression.

Authors:  Hui Zhi Low; Dorothee Hilbrans; Ingo G H Schmidt-Wolf; Harald Illges
Journal:  Int J Hematol       Date:  2012-08-17       Impact factor: 2.490

4.  Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy.

Authors:  Ken H Young; Dahua Zhang; Jeffery T Malik; Eliot C Williams
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

5.  Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti-beta2-glycoprotein-I autoantibodies.

Authors:  Anjana Singh; Miri Blank; Yehuda Shoenfeld; Harald Illges
Journal:  Rheumatol Int       Date:  2008-01-03       Impact factor: 2.631

6.  Systemic reduction of soluble complement receptor II/CD21 during pregnancy to levels reminiscent of autoimmune disease.

Authors:  Madhan Masilamani; Narendiran Rajasekaran; Anjana Singh; Hui-Zhi Low; Kerstin Albus; Swantje Anders; Frank Behne; Peter Eiermann; Katharina König; Clarissa Mindnich; Teodora Ribarska; Harald Illges
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

7.  Decreased levels of sCD21 and sCD23 in blood of patients with systemic-juvenile arthritis, polyarticular-juvenile arthritis, and pauciarticular-juvenile arthritis.

Authors:  Anjana Singh; Sebastiaan J Vastert; Berent J Prakken; Harald Illges
Journal:  Rheumatol Int       Date:  2011-02-17       Impact factor: 3.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.